Nasdaq · CIK 0001034842
RIGL RIGEL PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing 39 d ago. Close $49.08 on Oct 9, 2026, +93% from the 52-week low and -4% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
RIGLOct 9, 2026 · close 49.08
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at RIGEL PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Raymond J. Furey EVP, GC, CCO & Corp Sec sell | $60k 2,787 shares | -7% | - |
Transactions
The last 39 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Dean L Schorno EVP & Chief Financial Officer | FTax withholding Common Stock | -928 | $47.50 | $44k | 78,362 | 39 d ago |
| Sep 1, 2026 | David A Santos EVP, Chief Commercial Officer | FTax withholding Common Stock | -874 | $47.50 | $42k | 61,622 | 39 d ago |
| Sep 1, 2026 | Raul R Rodriguez CEO, President | FTax withholding Common Stock | -2,424 | $47.50 | $115k | 273,362 | 39 d ago |
| Sep 1, 2026 | Raymond J. Furey EVP, GC, CCO & Corp Sec | FTax withholding Common Stock | -877 | $47.50 | $42k | 50,559 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Common Stock | +694 | $12.70 | $8,814 | 79,056 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Common Stock | +620 | $18.70 | $12k | 79,676 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Common Stock | +2,000 | $24.20 | $48k | 81,676 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Common Stock | +1,286 | $24.20 | $31k | 82,962 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -694 | $0.00 | $0 | 12,824 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -620 | $0.00 | $0 | 9,012 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -2,000 | $0.00 | $0 | 7,999 | 39 d ago |
| Sep 2, 2026 | Dean L Schorno EVP & Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -1,286 | $0.00 | $0 | 15,867 | 39 d ago |
| Sep 15, 2025 | Raymond J. Furey EVP, GC, CCO & Corp Sec | AGrant or award Employee Stock Option (right to buy)derivative | +7,394 | $0.00 | $0 | 7,394 | Sep 17, 2025 |
| Sep 15, 2025 | Raul R Rodriguez CEO, President | AGrant or award Employee Stock Option (right to buy)derivative | +31,700 | $0.00 | $0 | 31,700 | Sep 17, 2025 |
| Sep 15, 2025 | Lisa Rojkjaer EVP, Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +7,394 | $0.00 | $0 | 7,394 | Sep 17, 2025 |
| Sep 15, 2025 | David A Santos EVP, Chief Commercial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +7,394 | $0.00 | $0 | 7,394 | Sep 17, 2025 |
| Sep 15, 2025 | Dean L Schorno EVP & Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +7,394 | $0.00 | $0 | 7,394 | Sep 17, 2025 |
| May 23, 2025 | Jane Wasman director | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 12,500 | May 28, 2025 |
| May 23, 2025 | Walter H Moos director | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 12,722 | May 28, 2025 |
| May 23, 2025 | Mark W Frohlich director | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 1,250 | May 28, 2025 |
| May 23, 2025 | Anthony Gregg Lapointe director | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 12,500 | May 28, 2025 |
| May 23, 2025 | Kamil Ali-Jackson director | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 9,375 | May 28, 2025 |
| May 23, 2025 | Alison L. Hannah director | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 10,625 | May 28, 2025 |
| May 23, 2025 | Alison L. Hannah director | AGrant or award Stock Option (Right to Buy)derivative | +3,000 | $0.00 | $0 | 3,000 | May 28, 2025 |
| May 23, 2025 | Mark W Frohlich director | AGrant or award Stock Option (Right to Buy)derivative | +1,500 | $0.00 | $0 | 1,500 | May 28, 2025 |
| May 23, 2025 | Anthony Gregg Lapointe director | AGrant or award Stock Option (Right to Buy)derivative | +3,000 | $0.00 | $0 | 3,000 | May 28, 2025 |
| May 23, 2025 | Kamil Ali-Jackson director | AGrant or award Stock Option (Right to Buy)derivative | +3,000 | $0.00 | $0 | 3,000 | May 28, 2025 |
| May 23, 2025 | Walter H Moos director | AGrant or award Stock Option (Right to Buy)derivative | +3,000 | $0.00 | $0 | 3,000 | May 28, 2025 |
| May 23, 2025 | Jane Wasman director | AGrant or award Stock Option (Right to Buy)derivative | +3,000 | $0.00 | $0 | 3,000 | May 28, 2025 |
| Mar 17, 2025 | Raymond J. Furey EVP, GC, CCO & Corp Sec | AGrant or award Employee Stock Option (right to buy)derivative | +9,375 | $0.00 | $0 | 9,375 | Mar 19, 2025 |
| Mar 17, 2025 | Raymond J. Furey EVP, GC, CCO & Corp Sec | AGrant or award Employee Stock Option (right to buy)derivative | +7,850 | $0.00 | $0 | 7,850 | Mar 19, 2025 |
| Mar 6, 2025 | Mark W Frohlich director | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Mar 10, 2025 |
| Feb 4, 2025 | Raymond J. Furey EVP, GC, CCO & Corp Sec | SOpen-market sale Common Stock | -1,448 | $20.92 | $30k | 40,169 | Feb 6, 2025 |
| Feb 5, 2025 | Raymond J. Furey EVP, GC, CCO & Corp Sec | SOpen-market sale Common Stock | -1,339 | $21.93 | $29k | 38,830 | Feb 6, 2025 |
| Jan 29, 2025 | Raymond J. Furey EVP, GC, CCO & Corp Sec | AGrant or award Common Stock | +19,717 | $0.00 | $0 | 41,617 | Jan 31, 2025 |
| Jan 29, 2025 | Raymond J. Furey EVP, GC, CCO & Corp Sec | AGrant or award Employee Stock Option (Right to Buy)derivative | +14,788 | $0.00 | $0 | 14,788 | Jan 31, 2025 |
| Nov 25, 2024 | Dean L Schorno EVP & Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +6,250 | $0.00 | $0 | 6,250 | Nov 26, 2024 |
| Nov 25, 2024 | Raul R Rodriguez CEO, President | AGrant or award Employee Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Nov 26, 2024 |
| Nov 25, 2024 | David A Santos EVP, Chief Commercial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +8,000 | $0.00 | $0 | 8,000 | Nov 26, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Kamil Ali-Jacksondirector
- Mark W Frohlichdirector
- Raymond J. FureyEVP, GC, CCO & Corp Sec
- Alison L. Hannahdirector
- Anthony Gregg Lapointedirector
- Walter H Moosdirector
- Raul R RodriguezCEO, President
- Lisa RojkjaerEVP, Chief Medical Officer
- David A SantosEVP, Chief Commercial Officer
- Dean L SchornoEVP & Chief Financial Officer
- Jane Wasmandirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.